The Latest Articles from Streetwise Reports
Virtual HealthCare Tech Firm Contracts to Provide Patient Care Platform to US Nephrology Clinic
News Update
Reliq Health Technologies reported it signed a new agreement with a Texas-based nephrology clinic to provide its iUGO Care platform to patients with chronic kidney disease.
read more >
Pandion Shares Trade Up 134% on $1.85 Billion Acquisition by Merck
Pandion Therapeutics shares reached a new 52-week high after the company reported it agreed to be acquired by pharmaceutical giant Merck & Co. in an all cash transaction for $60 per share. read more >Analyst: All Systems Are Go for Testing, Testing and More Testing
Research Report
This Dawson James report explains why ProPhase Labs is perfectly positioned to benefit from expanded COVID testing.
read more >
U.S. Cannabis Company 'Cashed Up with Catalysts Materializing'
Research Report
The many reasons why Columbia Care is 'due for a catch-up trade' are discussed in an Echelon Capital Markets report.
read more >
Owens & Minor Shares Soar 36% After Firm Reports Record Q4 Earnings and Positive 2021 Outlook
Shares of Owens & Minor Inc. soared to a new 52-week high after the company reported Q4/20 and FY/20 financial results that were boosted by a 58% gain in global products revenue and increases in elective medical procedures. read more >Telehealth Tech Company Continues Rapid Growth in COVID-Changed Landscape
Reliq Health introduces iUGO Home services and just added a care management network in California with 50 clinics and over 500 physicians. read more >Company's Antibiotic-Free Livestock Feed Product Shows Positive Results in Subclinical Mastitis Dairy Trial
News Update
Avivagen Inc. reported that data from a New Zealand OxC-betaT™ Livestock Dairy Trial for use against sub-clinical mastitis has been published in a top-tier international veterinary science journal.
read more >
Nektar Therapeutics Planning Phase 2/3 Studies with Merck and SFJ Pharma for Head and Neck Cancer
Nektar Therapeutics shares traded 14% higher after the company reported it plans to conduct a Phase 2/3 study of bempegaldesleukin in combination with Merck's KEYTRUDA® in patients with squamous cell carcinoma of the head and neck and is partnering on a second Phase 2/3 study with SFJ Pharmaceuticals that will provide $150 million to fund development. read more >Regenerative Medicine Firm Reports Positive Chronic Lower Back Pain Trial Results
Research Report
New study data and next steps for Mesoblast's MPC-06-ID are presented in a Dawson James Securities report.
read more >
Virtual HealthCare Tech Firm Contracts with California Network of 500+ Doctors and 50 Clinics
News Update
Reliq Health Technologies reported it signed a new contract with a care management network for its iUGO Care platform to deliver customized healthcare to senior citizens in the Asian-American community throughout California.
read more >
Digital Therapeutics Leader DarioHealth Makes a Critical Acquisition
Contributed Opinion
Independent financial analyst Matt Badiali discusses DarioHealth's latest acquisition and what it means for the company's growth.
read more >
PAVmed Shares Increase 28% after First US Patient Treated with CarpX Device for Carpal Tunnel Syndrome
PAVmed Inc. shares reached a new 52-week high after the company reported that the first patient in the U.S. was successfully treated with its CarpX® Device, a minimally invasive carpal tunnel release surgical instrument. read more >Pharma Developer Contemplates Adding Lung Scarring as Key Endpoint in Phase 2b/3 COVID-19 Trial
News Update
Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol.
read more >
ImmunoGen Shares Rise 30% After Firm Reports FY20 Earnings and 2021 Outlook
Shares of ImmunoGen Inc. reached a new 52-week high after the company announced Q4/20 and FY/20 business operating and financial results. read more >AC Immune Reports 'Positive Interim Results' from Novel Phase 1b/2a Alzheimer's Vaccine Trial
Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer's trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer's disease. read more >Pharmaceutical Developer Hires Laboratory to Conduct Preclinical Studies of Psychedelic Compound DMT
News Update
Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients.
read more >
Pacific Biosciences Shares Rise 22% on $900 Million Investment from Japan's SoftBank
Shares of Pacific Biosciences of California traded to a new 52-week high after the firm reported that a Softbank Group subsidiary will invest $900 million to support its growth initiatives. read more >Drug Repurposer Ventures into New Area, Use of Psychedelic in Stroke
Research Report
This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report.
read more >
Coverage Initiated on Firm Developing Gold Nanoparticle Therapy for Neurological Diseases
Research Report
The reasons Clene is a compelling investment are outlined in a ROTH Capital Partners report.
read more >
Small-Cap Psychedelic Wellness Company Makes First Acquisition: Ketamine Infusion Centers
DELIC aims to become a leader in psychedelic health and wellness clinics. read more >Align Technology Shares Grind 12.5% Higher after Firm Posts Record Q4 Revenue of $834.5 Million
Align Technology shares set a new 52-week high after the company announced financial results that included record FY/20 total revenues of $2.5 billion. read more >Neurosciences Firm Provides Insight on Recent Alzheimer's/Amyloid Field Developments
News Update
ProMIS Neurosciences offered its perspective on the latest progress in the Alzheimer's/Amyloid field. The firm stated that two recent positive events support the case for PMN310 to be considered "best in class."
read more >
GW Pharmaceuticals Shares Gain 46% on $7.2 Billion Acquisition by Jazz Pharmaceuticals
Shares of GW Pharmaceuticals reached a new 52-week high after the company reported it agreed to be acquired by Jazz Pharmaceuticals in a combination cash and stock deal for $220.00 per share. read more >Cassava Shares Triple After Interim Trial Data Shows Simufilam Improves Cognition and Behavior in Alzheimer's Disease
Shares of Cassava Sciences traded 207% higher after the firm provided an interim analysis from an ongoing study demonstrating that simufilam improves cognition and behavior in mild-to-moderate Alzheimer's disease patients. read more >Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics
Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share. read more >Showing Results: 1 to 25 of 168 Next